Gut microbiome in gastrointestinal cancer: a friend or foe? DOI Creative Commons
Yang Liu, Yoshifumi Baba, Takatsugu Ishimoto

et al.

International Journal of Biological Sciences, Journal Year: 2022, Volume and Issue: 18(10), P. 4101 - 4117

Published: Jan. 1, 2022

The impact of the gut microbiome on host health is becoming increasingly recognized.To date, there growing evidence that complex characteristics microbial community play key roles as potential biomarkers and predictors responses in cancer therapy.Many studies have shown altered commensal bacteria lead to susceptibility progression diverse pathways.In this review, we critically assess data for microbiota related gastrointestinal cancer, including esophageal, gastric, pancreatic, colorectal hepatocellular carcinoma cholangiocarcinoma.Importantly, underlying mechanisms involved occurrence, prevention treatment are elucidated.The purpose review provide novel insights applying understanding development new therapeutic strategies by targeting community.

Language: Английский

Current and future immunotherapeutic approaches in pancreatic cancer treatment DOI Creative Commons
Pooya Farhangnia, Hossein Khorramdelazad, Hamid Nickho

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: June 4, 2024

Abstract Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook and prognosis for this resistant type tumor have remained grim long time. Currently, it extremely challenging to prevent or detect early enough effective treatment because patients rarely exhibit symptoms there are no reliable indicators detection. Most advanced spreading that difficult treat, treatments like chemotherapy radiotherapy can only slightly prolong their life by few months. Immunotherapy has revolutionized pancreatic cancer, yet its effectiveness limited tumor's immunosuppressive hard-to-reach microenvironment. First, article explains microenvironment highlights wide range immunotherapy options, including therapies involving oncolytic viruses, modified T cells (T-cell receptor [TCR]-engineered chimeric antigen [CAR] T-cell therapy), CAR natural killer cell therapy, cytokine-induced cells, immune checkpoint inhibitors, immunomodulators, vaccines, strategies targeting myeloid in context contemporary knowledge future trends. Lastly, discusses main challenges ahead immunotherapy.

Language: Английский

Citations

34
Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death DOI Creative Commons
Zhenlong Li, Rui Ma,

Hejun Tang

et al.

Cell, Journal Year: 2024, Volume and Issue: 187(3), P. 624 - 641.e23

Published: Jan. 10, 2024

Language: Английский

Citations

28
The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer DOI Creative Commons
Bing Feng, Zhiliang Bai, Xiaolei Zhou

et al.

Nature, Journal Year: 2024, Volume and Issue: 634(8034), P. 712 - 720

Published: Sept. 25, 2024

Language: Английский

Citations

24
Robustness of cancer microbiome signals over a broad range of methodological variation DOI Creative Commons
Gregory D. Sepich‐Poore, Daniel McDonald, Evguenia Kopylova

et al.

Oncogene, Journal Year: 2024, Volume and Issue: 43(15), P. 1127 - 1148

Published: Feb. 23, 2024

Abstract In 2020, we identified cancer-specific microbial signals in The Cancer Genome Atlas (TCGA) [1]. Multiple peer-reviewed papers independently verified or extended our findings [2–12]. Given this impact, carefully considered concerns by Gihawi et al. [13] that batch correction and database contamination with host sequences artificially created the appearance of cancer type-specific microbiomes. (1) We tested comparing raw Voom-SNM-corrected data per-batch, finding predictive equivalence significantly similar features. found consistent results a modern microbiome-specific method (ConQuR [14]), when restricting to taxa an independent, highly-decontaminated cohort. (2) Using Conterminator [15], low levels human original databases (~1% genomes). demonstrated increased detection reads was due using newer genome reference. (3) developed Exhaustive, twice as sensitive Conterminator, clean RefSeq. comprehensively host-deplete TCGA many (pan)genome references. repeated all analyses pipeline, These extensive re-analyses updated methods validate conclusion signatures exist TCGA, show they are robust methodology.

Language: Английский

Citations

23
Roles of microbiota in pancreatic cancer development and treatment DOI Creative Commons
Mariana Santos Cruz, Joseph Tintelnot, Nicola Gagliani

et al.

Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)

Published: Feb. 27, 2024

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with poor prognosis. This due to the fact that most cases are only diagnosed at advanced and palliative stage, there a high incidence of therapy resistance. Despite ongoing efforts, date, mechanisms underlying PDAC oncogenesis its responses treatment still largely unclear. As study microbiome in cancer progresses, growing evidence suggests bacteria or fungi might be key players both as well resistance chemo- immunotherapy, for instance through modulation tumor microenvironment reshaping host immune response. Here, we review how microbiota exerts these effects directly indirectly via microbial-derived metabolites. Finally, further discuss potential modulating composition PDAC.

Language: Английский

Citations

21
The microbiota–gut–brain axis in Huntington's disease: pathogenic mechanisms and therapeutic targets DOI Creative Commons
Millicent N. Ekwudo, Carolina Gubert, Anthony J. Hannan

et al.

FEBS Journal, Journal Year: 2024, Volume and Issue: unknown

Published: March 1, 2024

Huntington's disease (HD) is a currently incurable neurogenerative disorder and typically characterized by progressive movement (including chorea), cognitive deficits (culminating in dementia), psychiatric abnormalities (the most common of which depression), peripheral symptoms gastrointestinal dysfunction). There are no approved disease‐modifying therapies available for HD, with death usually occurring approximately 10–25 years after onset, but some hold promising potential. HD subjects often burdened chronic diarrhea, constipation, esophageal gastric inflammation, susceptibility to diabetes. Our understanding the microbiota–gut–brain axis its infancy growing evidence from preclinical clinical studies suggests role gut microbial population imbalance (gut dysbiosis) pathophysiology. The brain can communicate through enteric nervous system, immune vagus nerve, microbiota‐derived‐metabolites including short‐chain fatty acids, bile branched‐chain amino acids. This review summarizes supporting demonstrating alterations bacterial fungal composition that may be associated HD. We focus on mechanisms dysbiosis compromise health, thus triggering neuroinflammatory responses, further highlight outcomes attempts modulate microbiota as therapeutic strategies Ultimately, we discuss dearth data need more longitudinal translational this nascent field. suggest future directions improve our association between microbes pathogenesis other ‘brain body disorders’.

Language: Английский

Citations

19
Tumor microenvironment as a complex milieu driving cancer progression: a mini review DOI Creative Commons
Zhengrui Li, Jing Li,

Xiaolei Bai

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 28, 2024

Language: Английский

Citations

19
Broadening oncological boundaries: the intratumoral microbiota DOI Creative Commons
Ying‐Qi Lu, Han Qiao,

Xi-Rong Tan

et al.

Trends in Microbiology, Journal Year: 2024, Volume and Issue: 32(8), P. 807 - 822

Published: Feb. 3, 2024

The microbiota of solid tumors was identified >100 years ago; however, heterogeneous composition and diversity have been revealed only recently. Growing evidence has suggested that several functional mechanisms the intratumoral affect tumorigenesis progression, suggesting is a promising biomarker for multiple cancers. low biomass poses major challenge to related research, thus necessitating use multiple-modality integrated framework resolve this dilemma. Advanced techniques such as single-cell sequencing provide significant clues, gradual optimization experiments culture-based methods enables deeper investigation underlying involved. In review, we outline current state research on describe challenges comprehensive strategies future research.

Language: Английский

Citations

18
Breast cancer: pathogenesis and treatments DOI Creative Commons
Xin Xiong,

Lewei Zheng,

Yu‐Qiang Ding

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 18, 2025

Abstract Breast cancer, characterized by unique epidemiological patterns and significant heterogeneity, remains one of the leading causes malignancy-related deaths in women. The increasingly nuanced molecular subtypes breast cancer have enhanced comprehension precision treatment this disease. mechanisms tumorigenesis progression been central to scientific research, with investigations spanning various perspectives such as tumor stemness, intra-tumoral microbiota, circadian rhythms. Technological advancements, particularly those integrated artificial intelligence, significantly improved accuracy detection diagnosis. emergence novel therapeutic concepts drugs represents a paradigm shift towards personalized medicine. Evidence suggests that optimal diagnosis models tailored individual patient risk expected are crucial, supporting era oncology for cancer. Despite rapid advancements increasing emphasis on clinical comprehensive update summary panoramic knowledge related disease needed. In review, we provide thorough overview global status including its epidemiology, factors, pathophysiology, subtyping. Additionally, elaborate latest research into contributing progression, emerging strategies, long-term management. This review offers valuable insights Cancer Research, thereby facilitating future progress both basic application.

Language: Английский

Citations

14
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer DOI Creative Commons
Masataka Amisaki, Abderezak Zebboudj, Hiroshi Yano

et al.

Nature, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Tertiary lymphoid structures (TLSs) are de novo ectopic aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)–LTβ receptor (LTβR) pathway1, inflammatory signals and cells induce remain incompletely identified. Here we show interleukin-33 (IL-33), alarmin released by tissues2, induces TLSs. In mice, Il33 deficiency severely attenuates inflammation- LTβR-activation-induced models colitis pancreatic ductal adenocarcinoma (PDAC). PDAC, domain IL-33 activates group 2 innate (ILC2s) expressing LT engage putative LTβR+ myeloid organizer initiate tertiary lymphoneogenesis. Notably, lymphoneogenic ILC2s migrate PDACs from gut, can be mobilized different tissues modulated gut microbiota. Furthermore, detect IL-33-expressing within human PDAC correlate with improved prognosis. To harness this pathway for immunotherapy, engineer a recombinant protein expands intratumoural demonstrates enhanced anti-tumour activity mice. summary, identify molecules druggable More broadly, reveal function alarmins ILC2s. structures.

Language: Английский

Citations

5